The growing interest in patient-reported outcomes may require FDA to come up with new ways to incorporate such data in drug labeling as it also explores alternative methods for communicating this information to patients.
At an April 25 workshop on clinical outcome assessments in cancer trials, FDA officials said the agency is trying to figure out how to present patient-reported outcomes (PRO) data within...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?